What's in Trans Tasman Radiation Oncology Group's pipeline?

Trans Tasman Radiation Oncology Group has 7 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Trans Tasman Radiation Oncology Group's portfolio?

Top competitors by shared drug class: AstraZeneca, Pfizer, Amgen, Dharmais National Cancer Center Hospital, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/trans-tasman-radiation-oncology-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Trans Tasman Radiation Oncology Group — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trans Tasman Radiation Oncology Group pipeline: 0 marketed, 0 filed, 5 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Post radiotherapy commencement of anastrozole	Post radiotherapy commencement of anastrozole	phase 3	Aromatase inhibitor	Aromatase (CYP19A1)	Oncology
Short Course Adjuvent Chemotherapy	Short Course Adjuvent Chemotherapy	phase 3	Chemotherapeutic agent		Oncology
Long Course Adjuvant Chemotherapy	Long Course Adjuvant Chemotherapy	phase 3	Chemotherapy regimen		Oncology
Sorbolene	Sorbolene	phase 3			Other
Pre-radiotherapy commencement of anastrozole	Pre-radiotherapy commencement of anastrozole	phase 3	aromatase inhibitor	aromatase	Oncology

Therapeutic area mix

Oncology · 4
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 2 shared drug classes
Pfizer · 2 shared drug classes
Amgen · 1 shared drug class
Dharmais National Cancer Center Hospital · 1 shared drug class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
CTI BioPharma · 1 shared drug class
Asan Medical Center · 1 shared drug class
All India Institute of Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Trans Tasman Radiation Oncology Group:

Cite this brief

Drug Landscape (2026). Trans Tasman Radiation Oncology Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/trans-tasman-radiation-oncology-group. Accessed 2026-05-17.